Banner
Browse by multiple fields below

Download csv Download xlsx
PDX ID Sample ID Patient Id Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site Current PDX Generation Average PDX Generation Time (days ± SEM) Tumour preparation2 Pubmed ID
201.1A 201.1A 201 Dura Autopsy 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 42 35 ± 2 Tumor solid 34413304; 30049486
201.1A Cx 201.1A 201 Dura Autopsy 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Castrate Subcutaneous 61 (30*) 39 ± 2 Tumor solid 34413304; 30049486
201.2A 201.2A 201 Lung Autopsy 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 31 39 ± 2 Tumor solid 34413304; 30049486
201.2A Cx 201.2A 201 Lung Autopsy 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Castrate Subcutaneous 26 (19*) 44 ± 2 Tumor solid 34413304; 30049486
330M 330M 330 Liver Biopsy 55-59 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 18 90 ± 9 Tumor solid 34413304
373M 373M 373 Liver Biopsy 65-69 NA 0.0 ADT Testosterone supplemented Subcutaneous 13 78 ± 7 Tumor solid 34413304
373M Cx 373M 373 Liver Biopsy 65-69 NA 0.0 ADT Castrate Subcutaneous 12 (2*) 92 ± 8 Tumor solid 34413304
374M 374M 374 Liver Biopsy 70-74 NA 0.0 ADT Testosterone supplemented Subcutaneous 12 94 ± 10 Tumor solid 34413304